The rush to judgment: Does the evidence support the enthusiasm over three-dimensional conformal radiation therapy and dose escalation in the treatment of prostate cancer?

International Journal of Radiation Oncology Biology Physics

Volumn 51, Issue 4, 2001, Pages 871-879

  Levitt, Seymour H ^a   Khan, Faiz M ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

bNED; Complications; Prostate cancer; Standard radiation therapy; Three dimensional conformal radiation therapy

Indexed keywords

DISEASES; DOSIMETRY; PATIENT TREATMENT; TUMORS;

CLINICAL EVIDENCE;

RADIOTHERAPY;

BRACHYTHERAPY; COMPLICATION; COMPUTER ASSISTED RADIOTHERAPY; DOSE RESPONSE; HUMAN; IMAGING; MALE; PATIENT SELECTION; PRIORITY JOURNAL; PROSTATE CANCER; RADIATION DOSE; REVIEW; RISK ASSESSMENT; SURVIVAL TIME; TECHNOLOGY; TREATMENT OUTCOME; TREATMENT PLANNING; TUMOR VOLUME;

CLINICAL TRIALS; EVIDENCE-BASED MEDICINE; HUMANS; MALE; MOVEMENT; PATIENT SELECTION; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIATION INJURIES; RADIOTHERAPY DOSAGE; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; RADIOTHERAPY, CONFORMAL; RECTUM; TREATMENT OUTCOME; URINARY BLADDER;

EID: 0035889274     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(01)01720-5     Document Type: Review

References (44)

1. Dr. Strange (high) tech or how I learned to stop worrying and love my MLC/3D treatment planning, stereotactic linac
2. Overpriced technology in radiation oncology
3. Optimization of prostate carcinoma staging; Comparison of imaging and clinical methods
4. A comparison of endorectal magnetic resonance imaging and transrectal ultrasonography in the local staging of prostate cancer with histopathological correlation
5. The effectiveness of imaging modalities in clinical staging of localized prostatic carcinoma
6. Prostate volumes defined by magnetic resonance imaging and computerized tomographic scans for three-dimensional conformal radiotherapy
7. Clinical variability of target volume descriptions in conformal radiotherapy planning
8. Immobilizing and positioning patients for radiotherapy
9. Evaluation of changes in the size and location of the prostate, seminal vesicles, bladder, and rectum during a course of external beam therapy
10. Effects of urethrography of prostate position; Considerations for radiotherapy treatment planning of prostate carcinoma
11. Treatment planning issues related to prostate movement in response to differential filling of the rectum and bladder
12. Evaluating the effect of rectal distension and rectal movement on prostate gland position using cine MRI
13. Prostate position late in the course of external beam therapy; patterns and predictors
14. A comparison of ventilatory prostate movement in four treatment positions
15. Molecular determination of surgical margins using fossa biopsies at radical prostatectomy
16. Redefining prostatic fossa radiation fields for adjuvant or salvage radiotherapy of prostate cancer
17. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer
18. Supra-lethal dose
19. Further improvements in dose distributions are unlikely to affect cure rates
20. 3D conformal radiation therapy (3DCRT) for high grade prostate cancer; A multi-institutional review
21. Dose escalation with 3D conformal treatment; Five year outcomes, treatment optimization, and future directions
22. Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer
23. Results of 3D conformal radiotherapy in the treatment of localized prostate cancer
24. Three-dimensional conformal therapy or standard irradiation in localized carcinoma of prostate; Preliminary results of a nonrandomized comparison
25. External beam radiotherapy dose response characteristics of 1127 men with prostate cancer treated in the PSA ERA
26. The treatment of nonpalpable PSA-detected adenocarcinoma of the prostate with 3-dimensional conformal radiation therapy
27. Defining the appropriate dose for pretreatment PSA<10 ng/ml prostate cancer
28. Dose escalation with 3D-CRT in prostate cancer; French study of dose escalation with conformal 3D radiotherapy in prostate cancer-preliminary results
29. Cost-benefit analysis of 3D conformal radiation therapy; Treatment of prostate cancer as a model
30. Optimizing patient selection for dose escalation techniques using the prostate-specific antigen level, biopsy gleason score, and clinical T-stage
31. Preliminary results of a randomized radiotherapy dose-escalation study comparing 70 Gy with 78 Gy for prostate cancer
32. Evidence based medicine; An approach to clinical problem-solving
33. A relationship of local prostate dose and subsequent metastases with 3D CRT in prostate cancer
34. The importance of adequate follow-up in defining treatment success after external beam irradiation for prostate cancer
35. What is the alpha/beta ratio for prostate cancer? Rationale for hypofractionated high-dose-rate brachytherapy
36. The natural history of localized prostate cancer; A guide to therapy
37. Consensus statement; Guidelines for PSA following radiation therapy
38. Tolerance of normal tissue to therapeutic irradiation
39. Estimation of the incidence of late bladder and rectum complications after high-dose (70-78 Gy) conformal radiotherapy for prostate cancer, using dose-volume histograms
40. Normal tissue complication probabilities correlated with late effects in the rectum after prostate conformal radiotherapy
41. Complications from radiotherapy dose escalation in prostate cancer; Preliminary results of a randomized trial
42. Three-dimensional conformal radiation therapy for early prostate cancer